Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among T1c HER2 Positive Patients

NCT06722599 is registered in ClinicalTrials.gov with Shu Wang as lead sponsor.

NCT NCT06722599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06722599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among T1c HER2 Positive Patients
Lead sponsor
Shu Wang
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2019
Completion date
December 31, 2028
Enrollment
171 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer